Jessica L. Mega, MD, MPH is a leader at the intersection of technology, life science, and health care. She is a Cardiologist at Stanford and Co-Founder of Verily, an Alphabet company applying AI and data science to accelerate evidence generation and enable more precise interventions to improve human health. She is on the Board of Directors at Boston Scientific Corporation and Danaher Corporation, and also serves on the Board of Advisors for Research!America and the Duke-Margolis Center for Health Policy.
As a faculty member at Harvard Medical School, a Senior Investigator with the TIMI Study Group, and a Cardiologist at Brigham and Women’s Hospital, Dr. Mega led large, international, randomized trials evaluating novel therapies. She also directed the TIMI Study Group’s Genomics Program, demonstrating and testing the role of CYP2C19 genetic variants on antiplatelet medications, a key pharmacogenetic finding. She has published manuscripts in the New England Journal of Medicine, Lancet, and JAMA. She served as an Advisor for the California Governor’s Precision Medicine Initiative.
Dr. Mega is a graduate of Stanford University, Yale University School of Medicine, and Harvard School of Public Health. She completed Internal Medicine Residency at Brigham and Women’s Hospital and Cardiovascular Fellowship at Massachusetts General Hospital. She is board certified in Internal Medicine and Cardiology. She has won the Laennec Society, Samuel A. Levine, and Douglas P. Zipes Awards, and she is a Fellow of the American Heart Association (AHA) and the American College of Cardiology (ACC).
Back to Board of Directors and Officers